| Bioactivity | Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC50 of 0.01 µM in PBMC cell. It is an antiviral drug for the treatment of HIV infection. | ||||||||||||
| Invitro | Emtricitabine has in vitro activity against both laboratory strains of HIV-1 and HIV-2 and clinical isolates of HIV-1. The 50% effective concentration (EC50) ranges from 0.002 to 1.5 µ mol/L, depending on the viral isolate and cell line used. Emtricitabine demonstrates in vitro synergy with zidovudine and stavudine and additive in vitro activity when combines with zalcitabine or didanosine[1]. | ||||||||||||
| Name | Emtricitabine | ||||||||||||
| CAS | 143491-57-0 | ||||||||||||
| Formula | C8H10FN3O3S | ||||||||||||
| Molar Mass | 247.25 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Emtricitabine
CAS: 143491-57-0 F: C8H10FN3O3S W: 247.25
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC50 of 0.01 µM in PBMC cell. It is an ant
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.